Carbamyl phosphate synthetase I (CPS I; EC6, 3, 4, 16 ) is an autosomal recessive disorder characterized, by hyperammonemia. We studied the molecular bases of CPS I deficiency in a newborn Japanese girl with consanguineous parents. Northern and Western blots revealed a marked decrease in CPS I mRNA and enzyme protein but with a size similar to that of the control, respectively. Sequencing of the patient's cDNA revealed a ninenucleotide deletion at position 832-840. Sequencing analysis of the genomic DNA revealed a G to C transversion at position 840, the last nucleotide of an exon in the splice donor site. This substitution altered the consensus sequence of the splice donor site and the newly cryptical donor site in the exon caused the 9-bp in-frame deletion. This report seems to be the first complete definition of CPS I deficiency, at the molecular level. (J.
Introduction
Carbamyl phosphate synthetase I (CPS I'; EC6, 3, 4, 16) , the first enzyme in ureagenesis, catalyzes the synthesis ofcarbamyl phosphate from HC03-, 2ATP, and NH4'. CPS I is a mitochondrial enzyme located in the matrix compartment and is expressed in the liver and in epithelial cells of intestinal mucosa (1) .
Deficiency in the enzyme results in an autosomal recessive disorder associated with hyperammonemia, protein intolerance, as well as impaired mental and physical development. The incidence of CPS I deficiency in Japan is 1:800,000 (2) . Two clinical patterns of CPS I deficiency have been described, the neonatal form (3) and the delayed onset form (4, 5) . The neonatal form is characterized by severe hyperammonemia from the neonatal period and sometimes results in neonatal death and the other form is milder in terms of protein intolerance. Enzyme defects are severe in the neonatal form and a partial deficiency can occur in the late onset form. Molecular events in the CPS I gene, as related to the enzyme defects have not been elucidated.
The enzyme, purified from a variety ofmammalian sources (6) (7) (8) , proved to be a single polypeptide with a molecular weight of 165,000. Human CPS I cDNA cloned and characterized in our laboratory showed that CPS I is composed of 1,500 amino acid residues, the calculated molecular weight of the precursor form is 164,828, and that of the processed mature form is 160,438 or 160,324 (9) .
Elucidation of the primary structure of the human CPS I prompted us to analyze CPS I deficiency, at the molecular level. We describe here an exon mutation that resulted in aberrant splicing and partial deletion in mRNA.
Methods
Patient. The patient was the progeny of first cousin parents and two siblings had died in the neonatal period. A severe hyperammonemia (956 gg/dl) associated with lethargy and grunting developed on the second postnatal day. Intensive treatment including exchange blood transfusion was ineffective and she died 4 d later. Liver CPS I activity decreased to 11% of the control.
Material. Liver samples taken from the patient within 1 h ofdeath were homogenized in the cold using 0.1% cetyltrimethyl-ammonium bromide at a 10:1 ratio ofbuffer volume/tissue wet weight. The homogenate was used for enzyme assay and Western blot analysis. The enzyme activity was measured by the method of Brown and Cohen (10).
Western blot analysis. SDS-PAGE was performed according to standard procedures (11) . Transfer onto nitrocellulose was done at 4VC for 14 h at 20 V in 20 mM Tris and 200 mM glycine (pH 8.3). Immunodetection was performed using an antiporcine CPS I polyclonal antibody prepared in our laboratory (12) . Protein concentrations were determined using BCA protein assay reagent kits supplied by Pierce Chemical Co. (Rockford, IL). Laser densitometry, using a computing densitometer (model 300-A; Molecular Dynamics, Sunnyvale, CA), was used to quantitate the relative signal intensity of the bands obtained.
Northern blot analysis. Total RNAs were isolated from the frozen autopsied liver and a human control liver, using the guanidium thiocyanate/cesium chloride centrifugation method (11) . 10 ttg oftotal RNA was denatured with 3% formaldehyde separated by electrophoresis in a 1.2% agarose gel, and transferred on to a nitrocellulose membrane. The filter was hybridized with 32P-labeled, full-length human CPS I cDNAs probe and a human arginase cDNA probe (9) . Prehybridization, hybridization, and wash were performed using standard procedures (11) . Autoradiography was done using an intensifying screen for 24 h at -70'C. The density of the obtained bands were measured by laser densitometer.
cDNA analysis. First strand cDNA was generated from 10 ug of total RNA, using Moloney murine leukemia virus reverse transcriptase (Bethesda Research Laboratories, Gaithersburg, MD) with specific antisense oligonucleotides primers (13) . PCR amplification of cDNA performed for 30 cycles consisted of denaturation 94'C for 1 min, annealing at 44°C for 1 min, and extension at 72°C for 3 min (14) . The amplified cDNAs were subcloned and nucleotide sequences of insert cDNA were determined (17 Northern blot analysis. Northern blot analysis of the total RNA from the liver of the patient revealed that the mRNA for CPS I was present and that the amount of the mRNA was markedly decreased to 3% of the control. The level of human arginase mRNA was 80% of the control (Fig. 1 B) . cDNA analysis. We synthesized cDNA for CPS I from the mRNA and amplified the entire coding region of the cDNA, using six pairs ofprimers (Fig. 2) , then the amplified fragments were subcloned and sequenced. Sequence analysis indicated a 9-bp deletion at positions 832-840 (Fig. 3 A) . No other mutation was detected in the coding region of CPS I cDNA. Genomic DNA analysis. To search for cause of the 9-bp deletion, we analyzed the CPS I gene. As the structure of human CPS I gene has not been elucidated, we obtained the gene fragment that covered the region of the mutation by screening of a genomic library. A phage clone named M-8 was found to cover the region of the mutation. Subsequently the nucleotide sequence of the phage clone was determined. The 9-bp sequence deleted from the mRNA of the patient was located in the 3' end of an exon composed of the coding sequence of nucleotide residues 832-840. We prepared a specific primer set which allows for amplification of the region related to the mutation (Fig. 2, MIA and M2B ). The nucleotide sequence ofthe amplified DNA from the controls and the patient revealed that DNA from the patient had a G to C transversion at position 840, the last nucleotide of the exon which confers a conserved sequence of the splice donor site (Fig. 4) . The G to C transversion at position 840 generated a new enzyme site of MaeII (5 '-A/CGT-3'). Thus, the PCR products from the patient and the controls, which included the splice donor site of the exon, were digested with MaeII. As expected, the DNA fragment from the patient but not from the control was cleaved into two fragments (Fig. 5) . Thus, the patient was homozygous for the G to C transversion. A family survey of the mutation revealed that the parents, the sister, and the brother were heterozygous for the G to C transversion (Fig. 5) . These studies confirmed that the mutation had been transmitted from the consanguineous parents. Analysis of mRNA and genomic DNA from the patient suggested that the 9-bp deletion in the mRNA was the result of aberrant splicing due to point mutation in the consensus sequence of the splice donor site of the exon.
We found that the human CPS I cDNA nucleotide sequence reported by Haraguchi et al. (9) had an error of one base addition of T at base number 834 (counted from ATG) and one base omission of A at base number 837.
The 9-bp deletion in the cDNA sequence provided a new restriction site for the enzyme SspI (5'-AAT/ATT-3'). As shown in Fig. 3 B, the 72-bp fragment obtained by PCR amplification (Fig. 2, MIA and M2A ) of the patient's cDNA was cleaved into 40-and 32-bp fragments. To investigate the presence of minor mRNA of a normal or different length, the cDNA fragment from the patient was reamplified after digestion with SspI, but no fragment was detected. A PCR fragment with primers A and B (Fig. 2) showed one band of an almost normal length, thus exon skipping had not occurred. These results suggest that almost all of the mature mRNA in the patient carried the 9-bp deletion.
Discussion
We obtained evidence for a point mutation in which the last nucleotide of the exon had G replaced with C in the CPS I gene in a CPS I deficient patient. As a result of the exon mutation a cryptical donor site appeared within the exon and there was a 9-bp deletion in the coding region in the mRNA (Fig. 6) .
While exon and which affect mRNA splicing. The precedents are thalassemia, the spf ash mutation at the ornithine transcarbamylase locus of mouse, and ry5208 mutation at the rosy (xanthine dehydrogenase) locus of Drosophila melanogaster (15) (16) (17) . ,B+ Thalassemia had the same G to C transversion at the last position of the exon. In the case of ,B+ thalassemia, the relative efficiency of the correct splicing of mRNA was decreased to 1.7% of the control. A scoring system described by Shapilo and Senapathy ( 18) gives a numerical value for any proposed 5' or 3' consensus sequence. The score ofproper splice site ofthe exon ofthe CPS I gene was decreased from 65.1 to 51.6% by the G to C transversion and the score of the newly appearing splicing site in the exon was 71.5%. A CPS I with normal length mRNA was not detected in the autopsied liver of the patient, as analyzed by PCR amplification. Almost the entire mRNA of CPS I appeared to be spliced, using the cryptical site, and the product seemed to be unstable, as deduced from Northern blots. The decreased production of mRNA might result in a deficiency in the mature form of CPS I protein.
The same mutation was absent in two other patients with CPS I deficiency (data not shown), thus the mutation may be heterogeneous in CPS I deficiency.
This report seems to be the first molecular analysis ofCPS I deficiency. A prenatal diagnosis and carrier detection ofCPS I deficiency is difficult because the enzyme is expressed only in the liver and intestine. Fetal liver biopsy for a prenatal diagnosis was done by other workers ( 19, 20) (21 ) . A DNA analysis of CPS I deficiency makes for safety and accuracy. Figure 6 . Organization of genomic, cDNA and amino acid sequence, as well as schematic representation of CPS I gene, together with the wild type and the patient's cDNA and amino acid sequence. The cDNA alteration seen in the mutant CPS I predicts the inframe deletion ofthe three amino acids. The mutation is underlined.
